Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089736 | 0.76 | CACNA2D1 (0.40) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL21055841 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL22699603 | 0.74 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL21090182 | 0.74 | ELANE (0.44) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL15640126 | 0.63 | AR (0.33) | — | |
| SCHEMBL4865645 | 0.61 | KDM5B (0.46) | — | |
| SCHEMBL4317637 | 0.61 | KDM4E (0.31) | KDM4E | |
| SCHEMBL21064290 | 0.60 | CTSD (0.42) | KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL17977284 | 0.60 | PARP1 (0.59) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3563420 | 0.59 | GSK3B (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | claimed |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | KDM4E 47/4885ALDH1A1 4188/4885HPGD 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.